Bismuth Quadruple Therapy Versus Modified Bismuth Therapy for Helicobacter Pylori
Key facts
- Who runs it
- Reham Abdelkader Elkhouly
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 200 people enrolled
- Started
- 1 Sept 2023
- Ended
- 1 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bismuth added on triple therapy
- Quadruple therapy
- Record updated
- 11 September 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients aged ≥ 18 years
- Confirmed diagnosis of H. pylori infection
Who cannot take part
- Prior treatment for H. pylori infection
- Presence of any contraindication to the study medications
- History of antibiotic or PPI use within the month preceding enrollment
- History of hypersensitivity or allergic reaction to any of the study drugs
- Advanced chronic liver disease or renal disease
- Pregnant or lactating women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of the study is to compare the efficacy of 2 different regimens of treatment of gastric bacteria (H pylori) these are: quadruple bismuth therapy and clarithromycin triple therapy with add-on bismuth, in eradicating H. pylori.
Read full original descriptionShow less
The secondary objective of the study is detection of adverse effects and treatment compliance in both regimens.
The 2 groups in the trial
- Bismuth added on triple therapyTreatment being tested
100 patients received oral triple therapy with add-on bismuth in the form of (Bismuth subcitrate 240 mg twice daily, Clarithromycin 500 mg twice daily, Amoxicillin 1gm twice daily, (PPI) Esomeprazole 40 mg twice daily for 2 weeks).
- bismuth quadruple therapyExisting treatment, for comparison
100 patients received 14-day oral regimen comprising Bismuth subcitrate (240 mg twice daily), Doxycycline (100 mg twice daily), Metronidazole (500 mg three times daily), and Esomeprazole (40 mg twice daily).
Treatment: Quadruple therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Eradication of Helicobacter Pylori: A Comparative Randomized Controlled Trial of Bismuth Quadruple Therapy and Bismuth Add-on to Clarithromycin Triple Therapy
- Record updated
- 11 September 2026